Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic...

詳細記述

保存先:
書誌詳細
出版年:Antimicrob Agents Chemother
主要な著者: Acosta, Rima K., Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Xuelian, Garner, William, Lutz, Justin, Majeed, Sophia, SenGupta, Devi, Martin, Hal, Quirk, Erin, White, Kirsten L.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Microbiology 2019
主題:
Antiviral Agents
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496090/
https://ncbi.nlm.nih.gov/pubmed/30803969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02533-18
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料